Patents by Inventor Leonid Beigelman

Leonid Beigelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250092400
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: August 6, 2024
    Publication date: March 20, 2025
    Applicant: Janssen Pharmaceutica NV
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL
  • Patent number: 12252481
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: March 18, 2025
    Assignees: Aligos Therapeutics, Inc., Katholieke Universiteit Leuven
    Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
  • Publication number: 20250011789
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?—O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising additional modification including a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap. The siNA molecules may reduce or inhibit the production of hydroxysteroid dehydrogenase.
    Type: Application
    Filed: September 8, 2022
    Publication date: January 9, 2025
    Inventors: N. Tilani S. De Costa, Xuan Luong, Aneerban Bhattacharya, Leonid Beigelman, Jerome Deval, Saul Martinez Montero
  • Patent number: 12173025
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 24, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 12129469
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: October 29, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Publication number: 20240352464
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising additional modification including a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap. The siNA molecules may reduce or inhibit the production of hydroxysteroid dehydrogenase.
    Type: Application
    Filed: March 7, 2024
    Publication date: October 24, 2024
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Xuan Luong, Kellan Passow, Aneerban Bhattacharya, Saul Martinez Montero, Jerome Deval
  • Publication number: 20240309040
    Abstract: The present disclosure relates to compounds and compositions containing 5?-phosphoramidite nucleoside monomers, and methods of making and use.
    Type: Application
    Filed: May 23, 2024
    Publication date: September 19, 2024
    Applicant: Janssen BioPharma, Inc.
    Inventors: Sergei GRYAZNOV, Jin HONG, Vivek Kumar RAJWANSHI, Leonid BEIGELMAN
  • Patent number: 12077757
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: September 3, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Patent number: 12065428
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: August 20, 2024
    Assignees: Aligos Therapeutics, Inc., Katholieke Universiteit Leuven
    Inventors: Dorothée Alice Marie-Eve Bardiot, Koen Vandyck, Sandro Boland, Antitsa Dimitrova Stoycheva, Arnaud Didier Marie Marchand, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman
  • Patent number: 12030907
    Abstract: A method of making a compound represented by Formula (I): includes a reducing step, a protecting step, and a phosphitylating step, where X is NH; Y is OCF3, —O(CR42)aCR43, —O(CR42)bOCR43, or —O(CR42)b—CR4?CR42; Z is H; B is adenine (A), guanine (G), thymine (T), cytosine (C), uracil (U), 5-methylcytosine (5-me-C), or a protected version of A, G, T, C, U, or 5-me-C; each R1 is independently C1-6 alkyl or cycloalkyl; R2 is CH2CH2CN or C1-6 alkyl; or R1 and R2 together form an optionally substituted C1-6 cycloalkyl; R3 is H or PG; PG is a protecting group; R4 is independently in each instance H or F; a is 1 or 2; and b is 1, 2, or 3.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: July 9, 2024
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Jin Hong, Vivek Kumar Rajwanshi, Leonid Beigelman
  • Publication number: 20240199647
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 1, 2023
    Publication date: June 20, 2024
    Inventors: Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand, Koen Vandyck, David McGowan, Leonid Beigelman, Antitsa Dimitrova Stoycheva
  • Publication number: 20240182444
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 16, 2023
    Publication date: June 6, 2024
    Inventors: Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand, Koen Vandyck, David McGowan, Leonid Beigelman
  • Patent number: 11952365
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: April 9, 2024
    Assignees: Aligos Therapeutics, Inc., Katholieke Universiteit Leuven
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Vladimir Serebryany, Antitsa Dimitrova Stoycheva, Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand
  • Publication number: 20240109871
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 4, 2024
    Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
  • Patent number: 11939581
    Abstract: The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 26, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Megan Elizabeth Fitzgerald, Saul Martinez Montero, Aneerban Bhattacharya
  • Publication number: 20240018126
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
  • Publication number: 20240011029
    Abstract: Oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: September 26, 2022
    Publication date: January 11, 2024
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • Patent number: 11858913
    Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Patent number: 11851422
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: December 26, 2023
    Assignees: Katholieke Universiteit Leuven
    Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
  • Publication number: 20230390242
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 22, 2023
    Publication date: December 7, 2023
    Inventors: Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit